Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.

Blood - 9 May 2024

Othman Jad, Potter Nicola, Ivey Adam, Jovanovic Jelena, Runglall Manohursingh, Freeman Sylvie D, Gilkes Amanda, Thomas Ian, Johnson Sean, Canham Joanna, Cavenagh Jamie, Kottaridis Panagiotis, Arnold Claire, Ommen Hans Beier, Overgaard Ulrik Malthe, Dennis Mike, Burnett Alan, Wilhelm-Benartzi Charlotte, Dillon Richard, Russell Nigel H

Abstract excerpt

ABSTRACT: Selection of patients with NPM1-mutated acute myeloid leukemia (AML) for allogeneic transplant in first complete remission (CR1-allo) remains controversial because of a lack of robust data. Consequently, some centers consider baseline FLT3-internal tandem duplication (ITD) an indication for transplant, and others rely on measurable residual disease (MRD) status. Using prospective data from the United...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3
Share to Hematopoietic Stem Cell Transplantation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Induction Chemotherapy

Share to Leukemia, Myeloid, Acute

Share to Neoplasm, Residual

Share to Nucleophosmin

Share to Remission Induction

Share to Transplantation, Homologous

Source

Identifiers

PMID: 38364112
DOI: 10.1182/blood.2023023096

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.PMID 38364112Read ↗

Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association Group.Semantic proximity Read ↗

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML.Semantic proximity Read ↗

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read ↗

Prognostic impact of clinico-genetic characteristics and donor types in NPM1-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.Semantic proximity Read ↗

Pre-transplant Quantitative Determination of NPM1 Mutation Significantly Predicts Outcome of AIlogeneic Hematopoietic Stem Cell Transplantation in Patients with Normal Karyotype AML in Complete Remission.Semantic proximity Read ↗

Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.Semantic proximity Read ↗

Pre-MEASURE:<i>FLT3</i>-ITD and mutated<i>NPM1</i>measurable residual disease before allogeneic transplant in adults with AML in first remissionSemantic proximity Read ↗

Real-World Outcomes in NPM1-Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse.Semantic proximity Read ↗

Allogeneic hematopoietic stem cell transplantation and pre-transplant strategies in patients with NPM1-mutated acute myeloid leukemia: a single center experience.Semantic proximity Read ↗

Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.Semantic proximity Read ↗

Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission.Semantic proximity Read ↗

Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.